Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025
Published: December 9, 2025 Arcellx, Inc. (NASDAQ: ACLX) has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel (“anito-cel”) at the American Society of Hematology (ASH) 2025 meeting.